(d) incubating the first supernatant at a temperature of about75°C to about 85°C and for a time of about 10 minutes to about 60 minutes to produce a clarified supernatant containing fimbrial agglutinogens 2 and 3 and a second precipitate containing non-fimbrial agglutinogen contaminants;

(e) concentrating the clarified supernatant to produce a crude fimbrial agglutinogen solution by precipitating fimbrial agglutinogens 2 and 3 from the clarified supernatant by the addition of a polyethylene glycol to the clarified supernatant, separating the precipitated fimbrial agglutinogen 2 and 3 from the resulting supernatant and solubilizing the separated fimbrial agglutinogens 2 and 3; and

(f) purifying fimbrial agglutinogens 2 and 3 from the crude fimbrial agglutinogen solution to produce the fimbrial agglutinogen preparation comprising fimbrial agglutinogens 2 and 3.

10. (Twice Amended) The process of claim 1 wherein said precipitation is effected by adding polyethylene glycol of molecular weight about 8000 to the clarified supernatant to a concentration of about 3% to about 5 wt.% to effect precipitation of said agglutinogens from the clarified supernatant.

13. (Twice Amended) The process of claim 12 wherein said column chromatography includes SEPHADEX [Sephadex] 6B and/or PEI silica column chromatography.

REMARKS

Petition is hereby made under the provisions of 37 CFR 1.136(a) for an extension of three months of the period for response to the Office Action. The prescribed fee is enclosed.

The Examiner indicated that claim 10 as amended was non-responsive as a result of a clerical error in omitting the "%" sign after "wt" in line 4. Claim 10 now has been amended to correct this error.

The Examiner maintained rejection of claim 13 under 35 USC 112, second paragraph. The Examiner indicated that the trademark SEPHADEX should be capitalized in the claim. Claim 13 now has been amended in this respect,